NASDAQ:ATRC

AtriCure Stock Forecast, Price & News

$79.99
-0.69 (-0.86 %)
(As of 07/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$79.41
$81.27
50-Day Range
$71.13
$83.92
52-Week Range
$34.04
$84.43
Volume229,406 shs
Average Volume222,166 shs
Market Capitalization$3.65 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.07
30 days | 90 days | 365 days | Advanced Chart
Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.


AtriCure logo

About AtriCure

AtriCure, Inc. engages in the development, manufacture, and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in Mason, OH.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.50 out of 5 stars

Medical Sector

542nd out of 2,218 stocks

Surgical & Medical Instruments Industry

46th out of 185 stocks

Analyst Opinion: 1.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











AtriCure (NASDAQ:ATRC) Frequently Asked Questions

Is AtriCure a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AtriCure stock.
View analyst ratings for AtriCure
or view top-rated stocks.

What stocks does MarketBeat like better than AtriCure?

Wall Street analysts have given AtriCure a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AtriCure wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is AtriCure's next earnings date?

AtriCure is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for AtriCure
.

How can I listen to AtriCure's earnings call?

AtriCure will be holding an earnings conference call on Wednesday, August 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) released its earnings results on Monday, April, 26th. The medical device company reported ($0.38) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.38). The medical device company had revenue of $59.28 million for the quarter, compared to the consensus estimate of $56.24 million. AtriCure had a negative net margin of 22.89% and a negative trailing twelve-month return on equity of 10.49%.
View AtriCure's earnings history
.

How has AtriCure's stock been impacted by COVID-19 (Coronavirus)?

AtriCure's stock was trading at $35.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ATRC shares have increased by 126.7% and is now trading at $79.99.
View which stocks have been most impacted by COVID-19
.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share guidance of -1.150--1.150 for the period, compared to the Thomson Reuters consensus EPS estimate of $-1.160. The company issued revenue guidance of $252 million-$256 million, compared to the consensus revenue estimate of $250.29 million.

What price target have analysts set for ATRC?

8 equities research analysts have issued twelve-month target prices for AtriCure's shares. Their forecasts range from $75.00 to $102.00. On average, they anticipate AtriCure's stock price to reach $86.25 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price.
View analysts' price targets for AtriCure
or view top-rated stocks among Wall Street analysts.

Who are AtriCure's key executives?

AtriCure's management team includes the following people:

What is Michael Carrel's approval rating as AtriCure's CEO?

25 employees have rated AtriCure CEO Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among AtriCure's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Fulton Bank N.A. (0.01%). Company insiders that own AtriCure stock include David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends for AtriCure
.

Which major investors are buying AtriCure stock?

ATRC stock was bought by a variety of institutional investors in the last quarter, including Fulton Bank N.A.. Company insiders that have bought AtriCure stock in the last two years include Regina E Groves, and Scott William Drake.
View insider buying and selling activity for AtriCure
or or view top insider-buying stocks.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $79.99.

How much money does AtriCure make?

AtriCure has a market capitalization of $3.65 billion and generates $206.53 million in revenue each year. The medical device company earns $-48,150,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does AtriCure have?

AtriCure employs 750 workers across the globe.

What is AtriCure's official website?

The official website for AtriCure is www.atricure.com.

Where are AtriCure's headquarters?

AtriCure is headquartered at 7555 INNOVATION WAY, MASON OH, 45040.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at (513) 755-4100.


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.